Description

Pembrolizumab (Keytruda) is a monoclonal antibody used to treat a variety of cancers, including:
Skin cancerPembrolizumab is used to treat melanoma, Merkel cell carcinoma, and cutaneous squamous cell carcinoma. It can be used to prevent melanoma from returning after surgery.
Lung cancerPembrolizumab is used to treat non-small-cell lung cancer (NSCLC). It can be used to prevent NSCLC from returning after surgery and platinum-based chemotherapy.
Head and neck cancerPembrolizumab is used to treat head and neck cancer.
Biliary tract cancerPembrolizumab is used to treat biliary tract cancer that has spread or cannot be removed by surgery. It is used in combination with gemcitabine hydrochloride and cisplatin.
Breast cancerPembrolizumab is used to treat triple negative breast cancer. It can be used in combination with chemotherapy for patients with breast cancer that has returned and cannot be removed by surgery.
Hodgkin’s lymphomaPembrolizumab is used to treat refractory classical Hodgkin lymphoma and in patients who have disease relapse after three or more lines of therapy.
Primary mediastinal B-cell lymphomaPembrolizumab is used to treat primary mediastinal large B-cell lymphoma that has not responded to treatment or has recurred.
Pembrolizumab works by helping the immune system slow or stop the growth of cancer cells.